Public Health Emergency - Leading a Nation Prepared
ASPR and Medicare built a suite of tools for public health authorities to support community COVID-19 response efforts, including a dashboard with population risks for COVID-19 hospitalization and death of Medicare beneficiaries down to the ZIP code, and more.
COVID-19 monoclonal antibody therapeutics are available at locations across the country to treat people who are at risk of developing severe symptoms. A new treatment locator can help you find a site near you where these meds have been delivered.
A third federally supported temporary monoclonal antibody infusion clinic started treating eligible COVID-19 patients today, thanks to collaboration between HHS/ASPR & Nevada DHHS. The facility will administer bamlanivimab to help keep people from becoming so sick that they require hospitalization.
HHS/ASPR is partnering with Tucson Medical Center & the Pima County Health Dept to help minimize the severity of COVID-19 in high risk patients by administering monoclonal antibody therapeutic treatments at a temporary COVID-19 infusion center. This center will provide treatments to eligible adult & pediatric COVID-19 patients over 12 years of age.
A new investigational COVID-19 therapeutic product by Merck to treat hospitalized patients and increase patient survival is moving forward with advanced development & manufacturing support from BARDA and JPEOCBRND under Operation Warp Speed.
Home | Contact Us | Accessibility | Privacy Policies | Disclaimer | HHS Viewers & Players | HHS Plain Language
Assistant Secretary for Preparedness and Response (ASPR), 200 Independence Ave., SW, Washington, DC 20201
U.S. Department of Health and Human Services | USA.gov |
HealthCare.gov in Other Languages